Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2190-9172
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data ; volume:13 ; number:1 ; day:10 ; month:12 ; year:2022 ; pages:269-283 ; date:1.2023
Dermatology and therapy ; 13, Heft 1 (10.12.2022), 269-283, 1.2023

Creator
Papp, Kim A.
Gooderham, Melinda
Dei-Cas, Ignacio
LopezTello, Adriana
Garcia-Rodriguez, Juan C.
Taveras, Carmen Yris
Rousselin, Azucena Hernández
Lavieri, Alberto
Maiolino, Mónica
Quintero, Delfina Guadalupe Villanueva
Rihakova, Lenka
Salibe, Mariano
Pertuz, Wilfran
Contributor
SpringerLink (Online service)

DOI
10.1007/s13555-022-00849-0
URN
urn:nbn:de:101:1-2023031522315354033265
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Papp, Kim A.
  • Gooderham, Melinda
  • Dei-Cas, Ignacio
  • LopezTello, Adriana
  • Garcia-Rodriguez, Juan C.
  • Taveras, Carmen Yris
  • Rousselin, Azucena Hernández
  • Lavieri, Alberto
  • Maiolino, Mónica
  • Quintero, Delfina Guadalupe Villanueva
  • Rihakova, Lenka
  • Salibe, Mariano
  • Pertuz, Wilfran
  • SpringerLink (Online service)

Other Objects (12)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis

Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis

Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry

Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08

Secukinumab (Plaque-Psoriasis) : Addendum zum Auftrag A17-08

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective

Secukinumab (Cosentyx) : frühe und effektive Behandlung mittelschwerer bis schwerer Plaque-Psoriasis

Secukinumab (Cosentyx) : frühe und effektive Behandlung mittelschwerer bis schwerer Plaque-Psoriasis

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis

Secukinumab(Plaque-Psoriasis) : Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse)

Secukinumab(Plaque-Psoriasis) : Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse)

Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Nutzenbewertung gemäß § 35a SGB V

Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-78

Secukinumab (Plaque-Psoriasis bei Kindern und Jugendlichen) : Addendum zum Auftrag A20-78

Related objects